Low back pain affects over 600 million people and is the single leading cause of disability worldwide. New research from ...
The groundbreaking CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK ...
Expanding the Clinical Value of Nociscan Beyond Surgical Decision Support ...
Do you suffer from low back pain that recurs regularly? If you do, you’re not alone. Roughly 70% of people who recover from an episode of low back pain will experience a new episode in the following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results